ArticleFrontiers in oncology2022
Small-Molecule Bi-DOTA Complex for High-Performance CT and Spectral CT Bioimaging.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Holmium vanadate nanoparticles as a biosafe and efficient contrast agent for spectral CT imaging of gastritis and colitis.Regenerative biomaterials · 2026Article
- Novel High-Atomic-Number Element and Nanoparticle-Based CT Contrast Agents: Advanced Design Strategies and Clinical Translational Barriers.International journal of nanomedicine · 2026Review
- Ultrasmall Bi/BiNanoscale advances · 2025Article
- Achieving safe and high-performance gastrointestinal tract spectral CT imaging with small-molecule lanthanide complex.Biomaterials research · 2023Article
- Bi-HPDO3A as a novel contrast agent for X-ray computed tomography.Scientific reports · 2023Article
- Hybrid FeWOInternational journal of nanomedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIt is necessary to develop a high-performance and biocompatible contrast agent to accurately diagnose various diseases MATERIALS AND
methodsIn our study, Bi-DOTA was fabricated through a facile and one-pot synthesis strategy. The formed Bi-DOTA complex was characterized
resultsA small molecular Bi-DOTA complex with a molecular mass of 0.61 kDa was synthesized successfully, which exhibited outstanding dispersion, good biocompatibility, and superior X-ray attenuation ability. Meanwhile, we showed that the obtained contrast agent was quite biocompatible and safe in the given concentration range as confirmed by
conclusionsThese superiorities allowed Bi-DOTA to be used as an efficient CT contrast agent and laid down a new way of designing high-performance CT contrast agents with great clinical transformation potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.